The major indices of the Indian stock markets suffered a correction on Monday and closed with losses over Friday’s close. On the NSE, there were 508 advances, 1,261 declines and 297 unchanged. The trends of the major indices in the course of Monday’s trading are given in the table below:
The key Indian equity indices managed to trade in the green initially. However, as the trading session progressed, the market correction set in and the major indices closed with losses.
Lending major HDFC Bank reported a 20.6% increase in its net profit to Rs5,005.73 crore during the quarter ended September 30, 2018, as compared to Rs4,151.03 crore in the year-ago period. The Bank's total income for the quarter under review was at Rs28,215.2 crore, up by 21.2% from Rs23,276.2 crore for the corresponding period last year. According to the lender, net interest income (interest earned less interest expended) for the period grew by 20.6% to Rs11,763.4 crore, from Rs9,752.1 crore for the year-ago quarter, driven by asset growth and a net interest margin for the quarter of 4.3%. HDFC Bank shares closed at Rs1,993.00, up 1.38% on the BSE.
Lupin has received approval for its Triamcinolone Acetonide Ointment USP, from the US FDA (Food and Drug Administration) to market a generic version of Mylan Pharma's Triamcinolone Acetonide Ointment. It is an anti-inflammatory ointment. Lupin shares closed at Rs883.35, up 0.35% on the NSE.
NBCC bagged two orders worth Rs1,376.53 crore for Redevelopment of Ayur Vigyan Nagar Campus of AIIMS (All India Institute of Medical Sciences) at New Delhi, Pkg.-I/Phase I (Order value: Rs837.77 crore) and Redevelopment of Charbagh, Lucknow Railway Station and adjoining Land Parcels (Order value: Rs538.76 crore). NBCC India shares closed at Rs53.30, up 0.95% on the BSE.
Gayatri Projects bagged three new orders worth Rs403.96 crore from Bihar State Road Development Corporation Limited (BSRDC). The company’s shares closed at Rs165.00, down 2.86% on the BSE.
Alembic Pharma has successfully cleared its first US FDA inspection of its new formulation manufacturing facility located at Karakhadi, Gujarat with zero observations. The company’s shares closed at Rs580.05, down 4.61% on the BSE.
Tejas networks has received a purchase order of Rs111 crore from Sterlite Technologies for Indian Navy’s country wide next generation digital communications network. Tejas would be supplying terabit capacity DWDM systems and high performance Layer-3 Multi Gigabit Ethernet switches. The company’s shares closed at Rs267.80, down 2.81% on the BSE.
Kansai Nerolac reported Q2 FY19 standalone results with net sales at Rs1,414.87 crore (Rs1,287.89 in the same period a year ago), up 9.9% year-on-year. Profit after tax was at Rs121.99 crore (Rs144.63 crore in the same period a year ago), down15.7% year-on-year. Earnings per share were at Rs2.26 (Rs2.68 in the same period a year ago).
Glaxosmithkline Pharma reported Q2 FY19 standalone results with revenues at Rs816.31 crore (Rs836.26 crore in the same period a year ago), down 2.4% year-on-year. Profit after tax was at Rs100.77 crore (Rs130.32 crore in the same period a year ago), down 22.7% year-on-year. Earnings per share were at Rs5.95 (Rs7.69 in the same period a year ago).
Jubilant Life Sciences reported Q2 FY19 consolidated results with total revenues of Rs2,269.49 crore (Rs1,642.04 crore in the same period a year ago), up 38.2% year-on-year. Net Profit was at Rs210.41 crore (Rs128.26 crore), up 64% year-on-year. Earnings per share were at Rs13.50 (Rs8.29 in the same period a year ago).
The top gainers and top losers of the major indices are given in the table below:
The closing values of the major Asian indices are given in the table below: